Lan Huang, Ph.D.

Dr. Huang is Founder, Chairman and CEO of BeyondSpring and SEED Therapeutics. Dr. Huang received scientific training at Memorial Sloan Kettering Cancer Center, where her breakthrough research in solving the first E2-E3 ubiquitin ligase structure involving P53 degradation was published in Science. She received her PhD in Chemistry from the University of California at Berkeley, where she won the graduating PhD woman award from Soroptimist International. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers. Dr. Huang has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry and invented and holds patents for a number of biotech products for oncology and dermatology indications. Prior to founding BeyondSpring and its pipeline of preclinical to Phase 3 assets, Dr. Huang co-founded WuXi MTLH Biotechnology Co. Ltd., and designed cancer peptide drug whose China rights were acquired in 2010 by Shanghai Pharmaceutical Group, one of the top three pharmaceutical companies in China. She also co-founded Paramax International, a clinical CRO company in China, sold to RPS (a global CRO), then to Warburg Pincus in 2011. At BeyondSpring, Dr. Huang has taken the company public (NASDAQ:BYSI) and advanced the main small molecule asset, plinabulin, through NDA filing in the US and China.